These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6998709)

  • 1. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.
    Calvert GD; Blight L; Franklin J; Oliver J; Wise P; Gallus AS
    Eur J Clin Pharmacol; 1980 May; 17(5):355-62. PubMed ID: 6998709
    [No Abstract]   [Full Text] [Related]  

  • 2. Clofibrate in insulin-dependent diabetes.
    Twomey C; Bloom A
    Ir J Med Sci; 1979 Feb; 148(2):31-5. PubMed ID: 478810
    [No Abstract]   [Full Text] [Related]  

  • 3. Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment.
    De Silva SR; Betteridge DJ; Shawe JE; Cudworth AG; Alberti KG
    Diabete Metab; 1979 Sep; 5(3):223-9. PubMed ID: 574098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man.
    Schade DS; Eaton RP; George S; Conway M; Kaminsky N; Sivinski J
    Metabolism; 1978 Apr; 27(4):461-8. PubMed ID: 416322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clofibrate administration on plasma post-heparin lipolytic activity in man.
    Maruhama Y; Yanbe A; Abe R; Oneda A; Yamagata S
    Tohoku J Exp Med; 1974 Aug; 113(4):343-9. PubMed ID: 4446025
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
    Ferrari C; Testori GP; Bertazzoni A; Romussi M; Caldara R; Frezzati S
    Horm Metab Res; 1978 Jan; 10(1):4-6. PubMed ID: 631736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.
    Daubresse JC; Daigneux D; Bruwier M; Luyckx A; Lefebvre PJ
    Br J Clin Pharmacol; 1979 Jun; 7(6):599-603. PubMed ID: 380614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
    Lithell H; Boberg J; Hedstrand H; Hellsing K; Ljunghall S; Vessby B
    Eur J Clin Pharmacol; 1977 Aug; 12(1):51-7. PubMed ID: 332503
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term monitoring during clofibrate therapy.
    Vester JW; Sunder JH; Aarons JH; Danowski TS
    Clin Pharmacol Ther; 1970; 11(5):689-97. PubMed ID: 5460240
    [No Abstract]   [Full Text] [Related]  

  • 10. [Triglycerides, free fatty acids and cholesterol after fat loading and heparin injection in diabetics with and without hyperlipoproteinemia as well as after clofibrate treatment].
    Singer P; Gnauck G; Honigmann G; Thoelke H; Schliack V; Läuter J
    Dtsch Z Verdau Stoffwechselkr; 1977; 37(1):27-37. PubMed ID: 913315
    [No Abstract]   [Full Text] [Related]  

  • 11. Type V hyperlipoproteinaemia. Metabolic changes in hyperlipaemic and previously hyperlipaemic ("susceptible") male patients.
    Jacobsen BB
    Atherosclerosis; 1973; 17(3):471-81. PubMed ID: 4577010
    [No Abstract]   [Full Text] [Related]  

  • 12. Carbohydrate-induced hypertriglyceridaemia in a child.
    Segall MM; Fosbrooke AS; Lloyd JK; Wolff OH
    Arch Dis Child; 1970 Feb; 45(239):73-9. PubMed ID: 5440210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
    Enger SC; Johnsen V; Samuelsen A; Laws EA
    Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
    Feldman EB; Gluck FB; Carter AC
    J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory indices in clofibrate therapy of juvenile-onset diabetes.
    Narduzzi JV; Danowski TS; Weir TF; Alley RA; Vester JW; Moses C
    Clin Pharmacol Ther; 1967; 8(6):817-23. PubMed ID: 4862480
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical-experimental studies on lipid metabolism using Regelan].
    Hammerl H
    Wien Klin Wochenschr; 1967 Sep; 79(39):720-2. PubMed ID: 4875575
    [No Abstract]   [Full Text] [Related]  

  • 18. Ageing, metabolic immunodepression and carcinogenesis.
    Dilman VM
    Mech Ageing Dev; 1978 Sep; 8(3):153-73. PubMed ID: 211354
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus.
    Ferrari C; Romussi M; Bertazzoni A; Testori GP; Grimaldi MG
    Biomedicine; 1978 Jun; 29(4):133-6. PubMed ID: 556385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
    Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
    Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.